Literatur
-
1
Acute Infarction Ramipril Efficacy (AIRE) Study Investigators .
Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure.
Lancet.
1993;
342
821-828
-
2
Ahmed A, Kiefe C I, Allman R M, Sims R V, DeLong J F.
Survival benefits of angiotensin-converting enzyme inhibitors in older heart failure patients with perceived contraindications.
J Am Geriatr Soc.
2002;
50
1659-1666
-
3
Barnes N M, Cheng C H, Costall B, Naylor R J, Williams T J, Wischik C M.
Angiotensin converting enzyme density is increased in temporal cortex from patients with Alzheimer’s disease.
Eur J Pharmacol.
1991;
200
289-292
-
4
Böhm M, Lippoldt A, Wienen W, Ganten D, Bader M.
Reduction of cardiac hypertrophy in TGR(mREN2)27 by angiotensin II receptor blockade.
Mol Cell Biochem.
1996;
163 - 164
217-221
-
5
Brilla C G, Reams G P, Maisch B, Weber K T.
Renin-angiotensin system and myocardial fibrosis in hypertension: regulation of the myocardial collagen matrix.
Eur Heart J.
1993;
14
57-61
(Suppl J)
-
6
Bulpitt C, Fletcher A, Beckett N, Coope J, Gil-Extremera B, Forette F, Nachev C, Potter J, Sever P, Staessen J, Swift C, Tuomilehto J.
Hypertension in the Very Elderly Trial (HYVET): protocol for the main trial.
Drugs Aging.
2001;
18
151-164
-
7
Clarkson P B, Wheeldon N M, MacLeod C, Tennent M, MacDonald T M.
Effects of angiotensin II and aldosterone on diastolic function in vivo in normal man.
Clin Sci (Lond).
1994;
87
397-401
-
8
Dostal D E, Hunt R A, Kule C E, Bhat G J, Karoor V, McWhinney C D, Baker K M.
Molecular mechanisms of angiotensin II in modulating cardiac function: intracardiac effects and signal transduction pathways.
J Mol Cell Cardiol.
1997;
29
2893-2902
-
9
Ford C M, Li S, Pickering J G.
Angiotensin II stimulates collagen synthesis in human vascular smooth muscle cells. Involvement of the AT(1) receptor, transforming growth factor-beta, and tyrosine phosphorylation.
Arterioscler Thromb Vasc Biol.
1999;
19
1843-1851
-
10
Forette F, Seux M L, Staessen J A, Thijs L, Babarskiene M R, Babeanu S, Bossini A, Fagard R, Gil-Extremera B, Laks T, Kobalava Z, Sarti C, Tuomilehto J, Vanhanen H, Webster J, Yodfat Y, Birkenhager W H.
The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study.
Arch Intern Med.
2002;
162
2046-2052
-
11
Gabrielsen A, Bie P, Christensen N J, Frandsen E, Galatius S, Pump B, Sorensen V B, Kastrup J, Norsk P.
Systemic vascular resistance during brief withdrawal of angiotensin converting enzyme inhibition in heart failure.
Scand J Clin Lab Invest.
2002;
62
245-254
-
12
Geisterfer A A, Peach M J, Owens G K.
Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells.
Circ Res.
1988;
62
749-756
-
13
Hall A S, Murray G D, Ball S G.
Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study.
Lancet.
1997;
349
1493-1497
-
14
Hansson L, Lindholm L H, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanmaki K, Dahlof B, de Faire U, Morlin C, Karlberg B E, Wester P O, Bjorck J E.
Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial.
Lancet.
1999;
353
611-616
-
15
Hu J, Igarashi A, Kamata M, Nakagawa H.
Angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide (A beta ): retards A beta aggregation, deposition, fibril formation, and inhibits cytotoxicity.
J Biol Chem.
2001;
276
47 863-47 868
-
16
Hutcheon S D, Gillespie N D, Crombie I K, Struthers A D, McMurdo M E.
Perindopril improves six minute walking distance in older patients with left ventricular systolic dysfunction: a randomised double blind placebo controlled trial.
Heart.
2002;
88
373-377
-
17
Insua J T, Sacks H S, Lau T S, Lau J, Reitman D, Pagano D, Chalmers T C.
Drug treatment of hypertension in the elderly: a meta-analysis.
Ann Intern Med.
1994;
121
355-362
-
18
Jong P, Yusuf S, Rousseau M F, Ahn S A, Bangdiwala S I.
Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study.
Lancet.
2003;
361
1843-1848
-
19
Libby P, Sukhova G, Lee R T, Liao J K.
Molecular biology of atherosclerosis.
Int J Cardiol.
1997;
62
S23-S29
(Suppl 2)
-
20
Linz W, Jessen T, Becker R H, Scholkens B A, Wiemer G.
Long-term ACE inhibition doubles lifespan of hypertensive rats.
Circulation.
1997;
96
3164-3172
-
21
Lucius R, Gallinat S, Busche S, Rosenstiel P, Unger T.
Beyond blood pressure: new roles for angiotensin II.
Cell Mol Life Sci.
1999;
56
1008-1019
-
22
Masoudi F A, Havranek E P, Wolfe P, Gross C P, Rathore S S, Steiner J F, Ordin D L, Krumholz H M.
Most hospitalized older persons do not meet the enrollment criteria for clinical trials in heart failure.
Am Heart J.
2003;
146
250-257
-
23
Morisco C, Condorelli M, Crepaldi G, Rizzon P, Zardini P, Villa G, Argenziano L, Trimarco B.
Lisinopril in the treatment of congestive heart failure in elderly patients: comparison versus captopril.
Cardiovasc Drugs Ther.
1997;
11
63-69
-
24
Nickenig G, Harrison D G.
The AT(1-type angiotensin receptor in oxidative stress and atherogenesis: part I: oxidative stress and atherogenesis.)
Circulation.
2002;
105
393-396
-
25
Nonoguchi H, Kiyama S, Inoue H, Nakayama Y, Inoue T, Kohda Y, Machida K, Tajima A, Kitamura K, Miyoshi T, Shimada H, Shimada H, Tajiri M, Honda Y, Tanaka M, Tomita K.
Angiotensin-converting enzyme inhibitor withdrawal and ACE gene polymorphism.
Clin Nephrol.
2003;
60
225-232
-
26
Olivetti G, Melissari M, Capasso J M, Anversa P.
Cardiomyopathy of the aging human heart. Myocyte loss and reactive cellular hypertrophy.
Circ Res.
1991;
68
1560-1568
-
27
O`Keeffe S, Harvey G, Lye M.
Use of angiotensin-converting enzyme inhibitors in elderly patients with heart failure.
Age and Ageing.
1998;
27
297-301
-
28
Pfeffer M A, Swedberg K, Granger C B, Held P, McMurray J J, Michelson E L, Olofsson B, Ostergren J, Yusuf S, Pocock S.
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme.
Lancet.
2003;
362
759-766
-
29
Pflugfelder P W, Baird M G, Tonkon M J, DiBianco R, Pitt B.
Clinical consequences of angiotensin-converting enzyme inhibitor withdrawal in chronic heart failure: a double-blind, placebo-controlled study of quinapri. The Quinapril Heart Failure Trial Investigators.
J Am Coll Cardiol.
1993;
22
1557-1563
-
30
Piccoli G B, Anania P, Biancone L, Mezza E, Vischi M, Jeantet A, Rabbia C, Savio D, Rossatto D, Gai M, Perin P C, Segoloni G P.
Hypertensive rebound after angiotensin converting enzyme inhibitor withdrawal in diabetic patients with chronic renal failure.
Nephrol Dial Transplant.
2001;
16
1084-1085
-
31
Pitt B, Poole-Wilson P A, Segal R, Martinez F A, Dickstein K, Camm A J, Konstam M A, Riegger G, Klinger G H, Neaton J, Sharma D, Thiyagarajan B.
Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II.
Lancet.
2000;
355
1582-1587
-
32
Pugh K G, Wei J Y.
Clinical implications of physiological changes in the aging heart.
Drugs Aging.
2001;
18
263-276
-
33
Ratnasabapathy Y, Lawes C M, Anderson C S.
The Perindopril Protection Against Recurrent Stroke Study (PROGRESS): clinical implications for older patients with cerebrovascular disease.
Drugs Aging.
2003;
20
241-251
-
34
Sadoshima J, Izumo S.
The cellular and molecular response of cardiac myocytes to mechanical stress.
Annu Rev Physiol.
1997;
59
551-571
-
35
Schunkert H, Jackson B, Tang S S, Schoen F J, Smits J F, Apstein C S, Lorell B H.
Distribution and functional significance of cardiac angiotensin converting enzyme in hypertrophied rat hearts.
Circulation.
1993;
87
1328-1339
-
36
Stephan D, Grima M, Welsch M, Barthelmebs M, Vasmant D, Imbs J.
Interruption of prolonged ramipril treatment in hypertensive patients: effects on the renin-angiotensin system.
Fundam Clin Pharmacol.
1996;
10
474-483
-
37
Takami T, Shigemasa M.
Efficacy of various antihypertensive agents as evaluated by indices of vascular stiffness in elderly hypertensive patients.
Hypertens Res.
2003;
26
609-614
-
38
Tatti P, Pahor M, Byington R P, Di Mauro P, Guarisco R, Strollo G, Strollo F.
Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM.
Diabetes Care.
1998;
21
597-603
-
39
The SOLVD Investigators .
Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.
N Engl J Med.
1991;
325
293-302
-
40
Wang Z Q, Moore A F, Ozono R, Siragy H M, Carey R M.
Immunolocalization of subtype 2 angiotensin II (AT2) receptor protein in rat heart.
Hypertension.
1998;
32
78-83
-
41
Wei J Y.
Age and the cardiovascular system.
N Engl J Med.
1992;
327
1735-1739
-
42
Yamakawa T, Tanaka S, Numaguchi K, Yamakawa Y, Motley E D, Ichihara S, Inagami T.
Involvement of Rho-kinase in angiotensin II-induced hypertrophy of rat vascular smooth muscle cells.
Hypertension.
2000;
35
313-318
-
43
Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G.
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators.
N Engl J Med.
2000;
342
145-153
Dr. Nikos Werner
Klinik für Innere Medizin III, Universitätsklinikum des Saarlandes
66421 Homburg-Saar
Phone: 06841/1623436
Fax: 06841/1623437
Email: werner@med-in.uni-sb.de
